Effectiveness of fixed-dose ezetimibe+simvastatin in real-life hypercholesterolaemia treatment: a retrospective observational study in Taiwan

References

• Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004;26:1758–1773.10.1016/j.clinthera.2004.11.016
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.10.1056/NEJMoa1410489
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, Backer G, et al. ESC/EAS guidelines for the management of dyslipidemias. Eur Heart J. 2011;32:1769–1818.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Rajagopalan S, Barnes JP, et al. Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting. Clin Ther. 2011;33:212–224.10.1016/j.clinthera.2011.02.011
   PubMed Web of Science ®Google Scholar
• Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe⁄simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – the IN-CROSS study. Int J Clin Pract. 2009;63:547–559.10.1111/ijcp.2009.63.issue-4
   PubMed Web of Science ®Google Scholar
• Gryn SE, Hegele R. Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2015;16:1255–1262.
   PubMed Web of Science ®Google Scholar
• Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol. 2011;22:460–466.10.1097/MOL.0b013e32834b4994
   PubMed Web of Science ®Google Scholar
• Branch WT, Higgins S. Clinical inertia: hard to move it forward. Rev Esp Cardiol. 2010;63:1399–1401.10.1016/S0300-8932(10)70265-7
   Web of Science ®Google Scholar
• Vijayakrishnan R, Kalyatanda G, Srinivasan I, et al. Compliance with the adult treatment panel III guidelines for hyperlipidemia in a resident-run ambulatory clinic: a retrospective data analysis. J Clin Lipidol. 2013;7:43–47.10.1016/j.jacl.2012.06.004
   Web of Science ®Google Scholar
• Altmann SW, David HR Jr., Zhu LJ, et al. Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–1204.10.1126/science.1093131
   PubMed Web of Science ®Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007;23:2183–2192.10.1185/030079907X226267
   PubMed Web of Science ®Google Scholar
• Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004;58:746–755.10.1111/ijcp.2004.58.issue-8
   PubMed Web of Science ®Google Scholar
• Feldman T, Koren M, Insull W Jr., et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain national cholesterol education program adult treatment panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004;93:1481–1486.10.1016/j.amjcard.2004.02.059
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Kawamura M, Kohro T, et al. Effect of ezetimibe on LDL-C lowering and atherogenic lipoprotein profiles in type 2 diabetic patients poorly controlled by statins. PLoS One. 2015;10:e0138332.10.1371/journal.pone.0138332
   PubMed Web of Science ®Google Scholar
• Bangalore S, Shahane A, Parkar S, et al. Compliance and fixed-dose combination therapy. Curr Hypertens Rep. 2007;9:184–189.10.1007/s11906-007-0033-3
   PubMed Web of Science ®Google Scholar
• Merck Sharp and Dohme. VYTORIN^® (ezetimibe and simvastatin) tablets | full prescribing information. Whitehouse Station (NJ): MSD International GmbH, a subsidiary of Merck. © 2004–2015: Revised 03/2015. [cited 2017 Feb 20] Available from: https://www.merck.com/product/usa/pi_circulars/v/vytorin/vytorin_pi.pdf
   Google Scholar
• Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410–414.10.1016/j.amjcard.2006.08.051
   PubMed Web of Science ®Google Scholar
• Kim HS, Wu Y, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the return on expenditure achieved for lipid therapy in Asia (REALITY-Asia) study. Curr Med Res Opin. 2008;24:1951–1963.10.1185/03007990802138731
   PubMed Web of Science ®Google Scholar
• Leiter LA, Betteridge DJ, Farnier M, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab. 2011;13:615–628.10.1111/j.1463-1326.2011.01383.x
   PubMed Web of Science ®Google Scholar
• de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2012;24:584–591.
   Web of Science ®Google Scholar
• Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res. 2010;40:566–573.10.1111/j.1872-034X.2010.00644.x
   PubMed Web of Science ®Google Scholar
• Sarigianni M, Katsiki N, Mikhailidis DP. Ezetimibe in diabetes: more than cholesterol lowering? Curr Med Res Opin. 2010;26:2517–2520.10.1185/03007995.2010.518519
   PubMed Web of Science ®Google Scholar
• Chang TY, Chang C. Ezetimibe blocks internalization of the NPC1L1/Cholesterol complex. Cell Metab. 2008;7:469–471.10.1016/j.cmet.2008.05.001
   Web of Science ®Google Scholar
• Naples M, Baker C, Lino M, et al. Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. AJP Gastrointest Liver Physiol. 2012;302:G1043–G1052.10.1152/ajpgi.00250.2011
   Web of Science ®Google Scholar
• Tamaki N, Ueno H, Morinaga Y, et al. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profile, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb. 2012;19:532–538.10.5551/jat.10835
   PubMed Web of Science ®Google Scholar
• World Health Organization Regional Office for the Western Pacific, International diabetes institute, international association for the study of obesity, international obesity task force. The Asia-Pacific perspective: redefining obesity and its treatment. Melbourne: Health Communications Australia; 2000 [cited 2017 Jun 23]. Available from: http://www.wpro.who.int/nutrition/documents/docs/Redefiningobesity.pdf
   Google Scholar
• Malhotra P, Boddy CS, Soni V, et al. D-Glucose modulates intestinal Niemann-Pick C1-like 1 (NPC1L1) gene expression via transcriptional regulation. AJP Gastrointest Liver Physiol. 2013;304:G203–G210.10.1152/ajpgi.00288.2012
   Web of Science ®Google Scholar
• Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302–1309.10.1001/jama.2012.366
   PubMed Web of Science ®Google Scholar